Pilgrim Global buys Sable Offshore (SOC) shares worth $14.7m
Director Connie Matsui of Sutro Biopharma (NASDAQ:STRO) acquired 50,000 shares of common stock on October 15, 2025, at a price of $0.799 per share. The total value of the purchase amounted to $39,950. The purchase comes as the stock trades near $0.78, down about 9% over the past week but up 44% over the last six months. According to InvestingPro analysis, STRO appears undervalued at current levels, with the stock trading 83% below its 52-week high of $4.60. Discover more insider trading patterns and 12 additional key insights with InvestingPro’s comprehensive analysis tools.
In other recent news, Sutro Biopharma announced an organizational restructuring that will reduce its workforce by approximately one-third. This strategic move is part of an effort to prioritize its antibody drug conjugate (ADC) programs and research collaborations. The restructuring, along with anticipated near-term milestone payments, is expected to extend the company’s financial runway into at least mid-2027. Sutro Biopharma has also reaffirmed its intention to file an Investigational New Drug (IND) application for STRO-004 in the second half of 2025. In addition, the company has entered into a collaboration with the U.S. Food and Drug Administration to develop reference materials for ADCs. This partnership aims to enhance regulatory standards and analytical methods for ADC drug development. Meanwhile, Citizens JMP analyst Reni Benjamin has reiterated a Market Perform rating on Sutro Biopharma following the company’s recent earnings announcement. These developments reflect Sutro Biopharma’s ongoing efforts to advance its ADC programs and strengthen its position in the industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.